Clinical trials · Maryland
Advanced Lung Non-Small Cell Carcinoma clinical trials in Maryland
We’re tracking 31 recruiting advanced lung non-small cell carcinoma studies with a site in Maryland — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Maryland
- NCT07154290RecruitingPhase 2
Ubamatamab with or without REGN7075 for advanced lung cancer
This trial tests a new targeted therapy (ubamatamab) alone or with another drug (REGN7075) for people with advanced or metastatic non-small cell lung cancer that has gotten worse after standard treatment. It aims to see if targeting MUC16, a substance found on some cancer cells, can help control the cancer.
Baltimore, MarylandAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Bethesda, MarylandAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Baltimore, MarylandAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Baltimore, MarylandAges 18 years+ - NCT04181060RecruitingPhase 3
Osimertinib alone or with bevacizumab for EGFR-mutant lung cancer
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
Bethesda, MarylandAges 18 years+ - NCT03191149RecruitingPhase 2
Osimertinib for lung cancer with an EGFR exon 20 change
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
Baltimore, MarylandAges 18 years+ - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
Bethesda, MarylandAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Baltimore, MarylandAges 18 years+ - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Baltimore, MarylandAges 18 years+ - NCT07222566RecruitingPhase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Annapolis, MarylandAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Annapolis, MarylandAges 18 years+ - NCT07144280RecruitingPhase 3
Study of a new drug vs docetaxel for advanced lung cancer
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Annapolis, MarylandAges 18 years+ - NCT06096844RecruitingPhase 3
Chemo plus immunotherapy vs immunotherapy alone for older adults with advanced lung cancer
This trial compares chemotherapy combined with immunotherapy to immunotherapy alone for adults 70 and older with advanced non-small cell lung cancer that has a specific protein level (PD-L1 1-49%). It aims to find which treatment works better for this group.
Baltimore, MarylandAges 70 years+ - NCT04486833RecruitingPhase 1/Phase 2
Genetic-targeted drug plus gene medicine for EGFR lung cancer
This trial studies a gene-based treatment added to osimertinib (a targeted lung cancer pill) for advanced EGFR-mutant lung cancer that has started growing again on osimertinib. It may help by attacking the cancer with both its usual target treatment and an added genetic approach.
Rockville, MarylandAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Early study of AZD8205 for advanced solid tumors
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
Baltimore, MarylandAges 18 years+ - NCT05211895RecruitingPhase 3
Durvalumab plus domvanalimab after chemoradiation for stage 3 lung cancer
This trial studies whether adding durvalumab and domvanalimab after standard chemoradiation can keep unresectable stage 3 lung cancer from coming back or getting worse. It targets tumors with specific lab test results (including PD-L1 and gene markers).
Baltimore, MarylandAges 18 years+ - NCT05236114Recruiting
Study of blood and tumor tests for lung cancer treatment
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
Baltimore, MarylandAges 18 years+ - NCT05498428RecruitingPhase 2
Amivantamab for advanced lung cancer with EGFR mutations
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
Baltimore, MarylandAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Rockville, MarylandAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Annapolis, MarylandAges 18 years+ - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Baltimore, MarylandAges 18 years+ - NCT05885698Recruiting
Study of care patterns in newly diagnosed lung cancer
This observational study follows adults with newly diagnosed non-small cell lung cancer to understand what treatments are used and how patients are doing. It may help doctors better understand how care decisions affect outcomes, and it does not require the study to give an experimental treatment.
Silver Spring, MarylandAges 18 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Baltimore, MarylandAges 18 years+ - NCT06031688RecruitingPhase 2
Targeted treatment for lung cancer with a MET gene change
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
Baltimore, MarylandAges 18 minutes+
Advanced Lung Non-Small Cell Carcinoma trials by city in Maryland
Where these studies are running in Maryland
Institutions with a site for the recruiting advanced lung non-small cell carcinoma studies listed above.
- Maryland Oncology Hematology, P.A. · 6 studies
- Maryland Oncology Hematology · 3 studies
- Research Site · 3 studies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 3 studies
- Johns Hopkins University · 2 studies
- Kaiser Permanente - Largo Medical Center · 2 studies
- Kaiser Permanente Gaithersburg Medical Center · 2 studies
- Kaiser Permanente Lutherville - Timonium Medical Center · 2 studies
What taking part in a advanced lung non-small cell carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced Lung Non-Small Cell Carcinoma trials in other states
Common questions
- Are there advanced lung non-small cell carcinoma clinical trials in Maryland?
- Yes. We're currently tracking 31 recruiting advanced lung non-small cell carcinoma studies with a site in Maryland, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced lung non-small cell carcinoma study in Maryland?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Maryland to take part?
- Not necessarily. These studies have a site in Maryland, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced lung non-small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced lung non-small cell carcinoma studies open in Maryland regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.